HCPCS Code A9502: Technetium Tc-99m tetrofosmin billing guide

Key Takeaways

HCPCS Code A9502 describes Technetium Tc-99m tetrofosmin (brand name Myoview), a radiopharmaceutical billed per study dose for myocardial perfusion imaging

Hospital outpatient departments have the drug cost packaged into APC 5593; physician offices and IDTFs bill separately based on AWP, ASP, or invoice price

A9502 is billed ‘per study dose,’ which affects how drug waste (Modifier JW) is applied – verify current CMS guidance before adding JW to this code

Pabau’s claims management software helps nuclear cardiology and radiology practices track radiopharmaceutical units, modifiers, and payer-specific rules in one place

HCPCS Code A9502: Definition, clinical use, and billing overview

Most nuclear cardiology claim errors trace back to a single root cause: incorrect unit reporting for the radiopharmaceutical. HCPCS Code A9502 is billed “per study dose,” not per millicurie, and that distinction drives how every downstream billing decision is made. When practices miss this, they either under-report units or incorrectly append modifiers that don’t apply, triggering denials that take weeks to resolve.

This reference covers the official code descriptor, clinical context, Medicare reimbursement methodology, modifier usage, related codes, and documentation requirements for HCPCS Code A9502. Nuclear cardiology billing teams, radiology coders, and IDTF administrators will find the billing rules most relevant to their daily workflows.

Code descriptor and clinical description

The official 2026 descriptor for HCPCS Code A9502 is: Technetium Tc-99m tetrofosmin, diagnostic, per study dose.

Tetrofosmin is a diphosphine ligand that, when labeled with Technetium-99m, creates a radiopharmaceutical taken up by viable myocardial tissue. Marketed under the brand name Myoview by GE Healthcare, it is used primarily in myocardial perfusion imaging (MPI) studies to assess coronary artery disease, ventricular function, and myocardial viability.

The code sits within the HCPCS Level II Diagnostic and Therapeutic Radiopharmaceuticals range (A9500-A9800), as maintained by the Centers for Medicare and Medicaid Services (CMS). This category covers radiopharmaceutical agents supplied for diagnostic imaging purposes.

Good patient data security in nuclear medicine workflows begin with accurate code identification at intake. Confirming A9502 at the point of service order prevents downstream mismatches between the administered agent and the billed code.

Billing rules and HCPCS Code A9502 reimbursement by setting

Reimbursement for A9502 varies significantly depending on the care setting. Three distinct billing environments apply different payment logic, and conflating them is one of the most common sources of underpayment.

Hospital outpatient departments

In the hospital outpatient setting, A9502 does not receive a separate line-item payment. The drug cost is packaged into the Ambulatory Payment Classification (APC) for the associated imaging procedure, historically APC 5593. Verify the current year’s APC assignment in the CMS Outpatient Prospective Payment System (OPPS) addendum annually, as APC assignments are updated each January.

Because payment is packaged, hospitals must still report A9502 on the claim for statistical and compliance purposes even though no separate payment issues for the radiopharmaceutical line.

Physician offices and IDTFs

Independent Diagnostic Testing Facilities (IDTFs) and physician offices bill A9502 under Medicare Part B and receive a separate payment. Reimbursement is typically calculated based on Average Wholesale Price (AWP), Average Sales Price (ASP), or the provider’s actual invoice price, depending on current CMS payment methodology for Part B radiopharmaceuticals. Verify the active payment basis in the CMS Physician Fee Schedule lookup for the applicable year.

Per the GE Healthcare Myoview Reimbursement Guide (2020), the physician office and IDTF payment is based on AWP, ASP, or invoice, and providers should ensure units reported are consistent with the study dose administered. Using claims management software that captures radiopharmaceutical lot information and administered dose at the time of service reduces the risk of unit inconsistencies surfacing at audit.

Check with your Medicare Administrative Contractor (MAC) for the specific payment rate in effect for your jurisdiction, as rates are updated quarterly.

Technical and professional component billing

A9502 is a supply code, not a professional service. It does not have a technical component (TC modifier) or professional component (Modifier 26) split. The radiopharmaceutical supply is billed by the facility that provides it, typically reported without these component modifiers.

If you are billing only the professional component of the associated imaging study (for example, the interpretation of the MPI), you would modify the CPT procedure code with Modifier 26, not the A9502 supply line.

Using clinical intake forms for diagnostic procedures that capture the care setting, supervising physician, and facility type at the time of scheduling gives billing staff the context they need to apply the correct payment rule from day one.

Modifier usage with HCPCS Code A9502

Modifier usage is the area most likely to cause audit risk with A9502. Two modifiers come up regularly in nuclear medicine billing workflows, and the rules around each are more nuanced than coders often expect.

Modifier JW: drug waste reporting

Modifier JW is used to report the amount of a Part B drug or biological that is discarded from a single-dose vial or package. CMS implemented mandatory JW reporting to track drug waste across radiopharmaceuticals and injectables.

The critical question for A9502 is whether JW applies when the code descriptor says “per study dose.” Because the code is already defined as a single study dose rather than a vial quantity, billing a separate waste line with JW is not straightforwardly supported. An AAPC forum discussion from January 2024 flagged this ambiguity, noting that the per-study-dose billing instruction may mean there is no waste to report separately.

Verify the current applicability of Modifier JW to A9502 with your MAC before appending it. Applying JW incorrectly can trigger claim edits or denials, while failing to report waste when required may create compliance exposure. This is flagged as uncertain in our research and must be confirmed against current CMS guidance for your jurisdiction.

Modifier JZ: zero waste attestation

CMS introduced Modifier JZ in 2023 as a companion to JW. When no drug is wasted from a single-dose container, providers attest to this by appending JZ. The same per-study-dose ambiguity for A9502 applies here. Confirm with your MAC whether JZ attestation is required or expected when billing A9502 under current policy.

Other relevant modifiers

Modifier GQ and GT (telehealth) do not apply to radiopharmaceutical supply codes. Modifier 59 (distinct procedural service) may be relevant in specific claim scenarios where multiple nuclear medicine agents are administered in the same session, but only when supported by documentation and an NCCI edit review. Review National Correct Coding Initiative (NCCI) edits for A9502 before billing it alongside other A-code radiopharmaceuticals in the same encounter.

Managing modifier logic across multiple payers and settings is where EHR integration for radiology billing workflows becomes operationally valuable. A system that flags modifier requirements at the claim-building stage reduces manual review time per claim.

Simplify radiopharmaceutical billing with Pabau

Pabau's claims management tools help nuclear medicine and cardiology practices track drug codes, modifiers, and payer rules without juggling spreadsheets.

Book a demo

CPT codes billed alongside HCPCS Code A9502

A9502 is a supply code, not a procedure code. It is always billed alongside the CPT code for the imaging study being performed. The two most common procedure codes associated with A9502 are listed below.

CPT code 78452

CPT 78452 describes myocardial perfusion imaging, tomographic (SPECT), with or without quantification, multiple studies (e.g. rest and stress). This is the primary procedure code for a complete MPI study and the most common companion code to A9502 in a nuclear cardiology billing scenario.

CPT code 93015

CPT 93015 describes a cardiovascular stress test using maximal or submaximal treadmill or bicycle exercise, continuous electrocardiographic monitoring, and physician supervision with interpretation and report. When a pharmacologic or exercise stress is performed as part of the MPI study, 93015 or its component codes (93016, 93017, 93018) may be reported alongside A9502 and 78452.

Per AAPC forum guidance, A9502 is billable by the facility providing the radiopharmaceutical. If billing only the professional component of the imaging study, you would not bill A9502, as the supply component belongs to the technical side of the service. Confirm NCCI bundling edits before billing 93015 and 78452 together to avoid automatic claim denials.

Practices using practice management software features for billing that support charge capture at the clinical workflow level can automate the pairing of supply codes like A9502 with their companion procedure codes, reducing manual coding errors.

Documentation requirements for HCPCS Code A9502

Medical necessity documentation is what separates a clean claim from one that triggers a pre-payment review or post-payment audit. For A9502, documentation must support both the supply of the radiopharmaceutical and the clinical indication for the imaging study.

Medical necessity

CMS Local Coverage Determinations (LCDs) L31072 and L31361 provide coverage criteria for myocardial perfusion imaging and associated radiopharmaceuticals. Documentation should reflect the clinical indication: known or suspected coronary artery disease, assessment of myocardial viability, evaluation following myocardial infarction, or pre-operative risk stratification.

The ordering physician’s notes must support why the MPI study was medically necessary, not just that it was ordered. A blanket order without clinical context supporting the indication creates audit risk even when the imaging findings are clinically significant.

Radiopharmaceutical administration record

The nuclear medicine or radiology department should maintain a record of the specific radiopharmaceutical administered, including the lot number, administered activity, and time of administration. This record links the supply to the clinical event and supports the billed code if payer documentation requests arise.

Maintaining HIPAA-compliant documentation practices for radiopharmaceutical records is particularly important given that these records contain patient health information tied to administered radioactive agents. Storage and access controls must meet HIPAA Security Rule requirements.

Payer-specific requirements

Commercial payers and Medicaid programs may have coverage policies that differ from Medicare LCDs. United Healthcare/Oxford published a Radiopharmaceuticals and Contrast Media policy that explicitly references A9502 alongside coverage criteria. MassHealth (Massachusetts Medicaid) lists A9502 with an “IC” (Individual Consideration) designation, meaning prior authorization may be required on a case-by-case basis.

Always verify payer-specific prior authorization requirements before the study date. A retrospective denial for lack of prior authorization on a radiopharmaceutical is difficult to overturn and typically cannot be billed to the patient.

Capturing authorization data alongside the patient record at scheduling, using digital intake forms that prompt staff to document payer-specific approval details, reduces the gap between clinical scheduling and billing readiness.

Related HCPCS codes and how A9502 compares

Several HCPCS codes describe similar Technetium-99m radiopharmaceuticals used in nuclear medicine. Understanding the distinctions prevents miscoding, particularly when a practice uses more than one agent across different study protocols.

A9500 vs A9501 vs A9502

All three codes fall within the same HCPCS radiopharmaceutical category and are billed per study dose. The distinction is the specific agent: A9500 is Technetium Tc-99m Sestamibi (brand name Cardiolite), A9501 is Technetium Tc-99m Teboroxime (Cardiotec), and A9502 is Technetium Tc-99m tetrofosmin (Myoview). Each agent has different pharmacokinetics, preparation requirements, and brand-name associations. Billing the wrong code because agents are ordered interchangeably at the institutional level is a common source of coding inaccuracy in high-volume nuclear cardiology settings.

Practices managing both Myoview and Cardiolite protocols need clear internal documentation of which agent was actually administered, not just which agent was ordered. Using medical practice management software with real-time inventory tracking helps confirm the administered agent before the billing team codes the claim.

Searching verified code references

For HCPCS lookup and crosswalk verification, the PGM Billing HCPCS lookup tool provides free searches using current CMS data. This is useful for confirming the active descriptor and checking for any code-level notes or billing instructions before submitting claims.

Tracking clinic software compliance requirements across payers is easier when your billing system stores payer policies alongside the active code set, reducing the need to cross-reference external sources on every claim.

Common denial reasons and how to avoid them

Radiopharmaceutical claims face a predictable set of denial patterns. Knowing them in advance gives billing teams a checklist to run before submission rather than a queue of remittance advice to resolve after the fact.

• Wrong unit reporting: A9502 is billed as one unit per study dose. Reporting multiple units for a single imaging study, or using millicurie quantities as the unit count, will generate claim edits. Confirm your billing system is set to report one unit per administered dose.
• Missing medical necessity documentation: Claims submitted without supporting clinical notes showing the indication for MPI are vulnerable to retrospective audit under Medicare LCD L31072. Ensure the ordering physician’s records are in the chart before billing.
• Incorrect modifier application: Appending JW to a per-study-dose code without verifiable waste documentation and MAC guidance creates an inconsistent claim record. Verify modifier applicability before submission.
• Setting-specific billing errors: Billing A9502 as a separate payable line from a hospital outpatient claim, where it is packaged, will generate a contractual adjustment at best and a rejection at worst.
• Prior authorization gaps: Commercial and Medicaid claims for A9502 may require prior authorization. Submitting without it when required results in a denial that is difficult to appeal retroactively.

Practices using structured forms for diagnostic procedure workflows that capture authorization status, ordering physician details, and administered agent at the point of care give their billing teams the complete picture needed to avoid each of these denial types.

How Pabau supports nuclear medicine and cardiology billing workflows

Nuclear cardiology and radiology practices deal with a billing environment more complex than most: radiopharmaceutical-specific codes, payer-by-payer coverage policies, modifier ambiguity, and setting-dependent payment rules all running in parallel. Manual workflows across these variables carry high error rates.

Pabau’s claims management software gives practices a structured environment to capture procedure and supply codes together at the point of service, apply modifier rules consistently, and track claim status across payers. For practices working across physician office and IDTF settings, consistent code and modifier application across both environments is essential for clean claim rates.

For practices exploring integrative medicine software that supports both clinical documentation and billing in a single platform, Pabau’s approach connects the point-of-care record to the billing workflow, reducing the hand-off errors that drive radiopharmaceutical claim denials. Explore how Pabau can support your billing team by visiting pabau.com/book-demo.

Continue your research

Need to track compliance across diagnostic procedures? Clinic software compliance requirements covers the key standards diagnostic practices need to meet.

Looking for a structured approach to practice billing? Claims management software outlines how Pabau handles multi-payer claim tracking and modifier rules.

Managing documentation across diagnostic settings? Clinical forms for healthcare practices explains how structured intake documentation supports billing accuracy from the point of service.

Frequently Asked Questions